Cargando…
A Systematic Review of the Safety of Lisdexamfetamine Dimesylate
BACKGROUND: Here we review the safety and tolerability profile of lisdexamfetamine dimesylate (LDX), the first long-acting prodrug stimulant for the treatment of attention-deficit/hyperactivity disorder (ADHD). METHODS: A PubMed search was conducted for English-language articles published up to 16 S...
Autores principales: | Coghill, David R., Caballero, Beatriz, Sorooshian, Shaw, Civil, Richard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4057639/ https://www.ncbi.nlm.nih.gov/pubmed/24788672 http://dx.doi.org/10.1007/s40263-014-0166-2 |
Ejemplares similares
-
Efficacy and Safety of Lisdexamfetamine Dimesylate and Atomoxetine in the Treatment of Attention-Deficit/Hyperactivity Disorder: a Head-to-Head, Randomized, Double-Blind, Phase IIIb Study
por: Dittmann, Ralf W., et al.
Publicado: (2013) -
Treatment Response and Remission in a Double-Blind, Randomized, Head-to-Head Study of Lisdexamfetamine Dimesylate and Atomoxetine in Children and Adolescents with Attention-Deficit Hyperactivity Disorder
por: Dittmann, Ralf W., et al.
Publicado: (2014) -
Post hoc analyses of the impact of previous medication on the efficacy of lisdexamfetamine dimesylate in the treatment of attention-deficit/hyperactivity disorder in a randomized, controlled trial
por: Coghill, David R, et al.
Publicado: (2014) -
Review of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder
por: Najib, Jadwiga, et al.
Publicado: (2017) -
Long-Term Safety and Efficacy of Lisdexamfetamine Dimesylate in Children and Adolescents with ADHD: A Phase IV, 2-Year, Open-Label Study in Europe
por: Coghill, David R., et al.
Publicado: (2017)